ResMed (NYSE: RMD) reported Q2 EPS of $1.47, $0.05 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $894.9 million versus the consensus estimate of $935.3 million.

For earnings history and earnings-related data on ResMed (RMD) click here.